Your browser doesn't support javascript.
loading
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
Xing, Fei; Gao, Hongli; Chen, Guanglei; Sun, Lisha; Sun, Jiayi; Qiao, Xinbo; Xue, Jinqi; Liu, Caigang.
Afiliação
  • Xing F; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Gao H; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Chen G; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Sun L; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Sun J; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Qiao X; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Xue J; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China.
  • Liu C; Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, 110022, China. liucg@sj-hospital.org.
Mol Cancer ; 22(1): 6, 2023 01 10.
Article em En | MEDLINE | ID: mdl-36627608
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Proteínas com Domínio MARVEL Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Mol Cancer Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Proteínas com Domínio MARVEL Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Mol Cancer Ano de publicação: 2023 Tipo de documento: Article